School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Institute of Clinical Evaluative Sciences, Ottawa, ON, Canada.
BMJ. 2023 Jun 22;381:e075062. doi: 10.1136/bmj-2023-075062.
To study age specific associations of modest reductions in estimated glomerular filtration rate (eGFR) with adverse outcomes.
Retrospective, population based cohort study.
Linked healthcare administrative datasets in Ontario, Canada.
Adult residents (18-65 years) with at least one outpatient eGFR value (categorized in 10 unit increments from 50 mL/min/1.73m to >120 mL/min/1.73m), with no history of kidney disease.
eGFRs and hazard ratios of composite adverse outcome (all cause mortality, any cardiovascular event, and kidney failure) stratified by age (18-39 years, 40-49 years, and 50-65 years), and relative to age specific eGFR referents (100-110 mL/min/1.73m) for ages 18-39 years, 90-100 for 40-49 years, 80-90 for 50-65 years).
From 1 January 2008 to 31 March 2021, among 8 703 871 adults (mean age 41.3 (standard deviation 13.6) years; mean index eGFR 104.2 mL/min/1.73m (standard deviation 16.1); median follow-up 9.2 years (interquartile range 5.7-11.4)), modestly reduced eGFR measurements specific to age were recorded in 18.0% of those aged 18-39, 18.8% in those aged 40-49, and 17.0% in those aged 50-65. In comparison with age specific referents, adverse outcomes were consistently higher by hazard ratio and incidence for ages 18-39 compared with older groups across all eGFR categories. For modest reductions (eGFR 70-80 mL/min/1.73m), the hazard ratio for ages 18-39 years was 1.42 (95% confidence interval 1.35 to 1.49), 4.39 per 1000 person years; for ages 40-49 years was 1.13 (1.10 to 1.16), 9.61 per 1000 person years; and for ages 50-65 years was 1.08 (1.07 to 1.09), 23.4 per 1000 person years. Results persisted for each individual outcome and in many sensitivity analyses.
Modest eGFR reductions were consistently associated with higher rates of adverse outcomes. Higher relative hazards were most prominent and occurred as early as eGFR <80 mL/min/1.73m in younger adults, compared with older groups. These findings suggest a role for more frequent monitoring of kidney function in younger adults to identify individuals at risk to prevent chronic kidney disease and its complications.
研究肾小球滤过率(eGFR)适度降低与不良结局的年龄特异性关联。
回顾性、基于人群的队列研究。
加拿大安大略省的医疗保健行政数据集。
至少有一次门诊 eGFR 值(按每 10 个单位分类,范围为 50 mL/min/1.73m 至>120 mL/min/1.73m),且无肾脏疾病史的成年居民(18-65 岁)。
根据年龄(18-39 岁、40-49 岁和 50-65 岁)和与年龄特定 eGFR 参照值(18-39 岁为 100-110 mL/min/1.73m,40-49 岁为 90-100 mL/min/1.73m,50-65 岁为 80-90 mL/min/1.73m)分层的复合不良结局(全因死亡率、任何心血管事件和肾衰竭)的 eGFR 比值和危险比。
从 2008 年 1 月 1 日至 2021 年 3 月 31 日,在 8703871 名成年人(平均年龄 41.3(标准差 13.6)岁;平均指数 eGFR 为 104.2 mL/min/1.73m(标准差 16.1);中位随访时间为 9.2 年(四分位间距 5.7-11.4))中,18-39 岁者中有 18.0%、40-49 岁者中有 18.8%、50-65 岁者中有 17.0%记录到与年龄相关的 eGFR 测量值适度降低。与年龄特定参照值相比,在所有 eGFR 类别中,18-39 岁者的不良结局发生率和危险比均高于年龄较大的组。对于适度降低(eGFR 70-80 mL/min/1.73m),18-39 岁者的危险比为 1.42(95%置信区间 1.35-1.49),每 1000 人年发生 4.39 例;40-49 岁者为 1.13(1.10-1.16),每 1000 人年发生 9.61 例;50-65 岁者为 1.08(1.07-1.09),每 1000 人年发生 23.4 例。这些结果在每个单独的结局和许多敏感性分析中均持续存在。
肾小球滤过率(eGFR)的适度降低与不良结局的发生率始终呈正相关。较高的相对危险度最显著,并且在年轻人的 eGFR<80 mL/min/1.73m 时就已出现,与年龄较大的组相比更为明显。这些发现表明,在年轻人中更频繁地监测肾功能以识别有风险的个体,以预防慢性肾脏病及其并发症,可能具有一定作用。